Prognostic significance of autoimmunity during treatment of melanoma with interferon.
about
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12HPV Carcinomas in Immunocompromised PatientsMelanoma-associated leukoderma - immunology in black and white?New perspectives on the role of vitiligo in immune responses to melanomaProgression of cutaneous melanoma: implications for treatmentToxicities of Immunotherapy for the PractitionerCancer vaccinesUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsMeta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant MelanomaAdvances in Cancer Immunotherapy in Solid TumorsA quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trialMonobenzone-induced depigmentation: from enzymatic blockade to autoimmunityType I interferon is selectively required by dendritic cells for immune rejection of tumorsThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkCancer immunotherapy comes of ageEmerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyMERTK receptor tyrosine kinase is a therapeutic target in melanoma.Data generation for the Cox proportional hazards model with time-dependent covariates: a method for medical researchers.Serum anti-BPAG1 auto-antibody is a novel marker for human melanomaDown-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.Utility of adjuvant systemic therapy in melanoma.Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Melanoma in pediatric, adolescent, and young adult patients.Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.Advanced malignant melanoma: immunologic and multimodal therapeutic strategiesIntranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanomaCombination immunotherapy for high-risk resected and metastatic melanoma patientsPilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in childrenImmunologic functions as prognostic indicators in melanomaInterferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine.Interferon-α abrogates tolerance induction by human tolerogenic dendritic cellsA polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaAssociation of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survivalSimultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.
P2860
Q26796316-260A26E6-EF62-46FE-B3CB-C9EF118BAFD0Q26799629-0B3723BE-F7F5-4CA6-BBE5-8A6F3B0957F7Q26850001-E26EDEF4-CBC0-4738-A32D-746DAFF2C7C0Q26996799-914700AC-3C7D-47EF-8385-EA1E5F7D5704Q27001734-2D7621F4-656D-450A-8AB4-EA61BD82F0E1Q27008140-3B8730A1-E540-441C-8D2D-E1A84D4406B5Q27024438-BF47DC69-F105-4131-94CB-051B53B1B4B5Q27691824-2EEAD25F-F7A2-4ED2-97C0-49E87C487926Q28067583-37371A27-2278-416D-9C88-A9931294C603Q28074939-CEF3EBF1-0540-4620-9F3B-683058C410D5Q28080113-3979CC78-AFFC-4417-A094-71339BA57D5EQ28088679-C51D8EE2-B374-4E4C-93B2-9FD363CA293AQ28241227-48C037C3-D83E-4D0D-A9D8-7148927E1452Q28248500-2D2E962A-3799-4852-A6AD-7AB3557960A3Q28485085-5706EA39-D4B8-4802-A150-ADDFD9924BC7Q29619918-61CE1EB2-3DB8-4F5F-A9F5-35753D7117B9Q30438965-AF281643-07E2-449C-BEE4-222EE7F33E9CQ30539324-22BF6D20-AE08-4E75-A084-9C4F353627ACQ30665555-B87CE67C-8E75-4C57-B2CC-39FA4C5F17D6Q30982790-A54EA0E0-25FB-4FD2-8750-EEA6096A530AQ33284046-EF8B80C9-0935-468B-9287-E2E2E2819121Q33464837-3B964682-9173-4B8A-A7D1-F80D219B4FEEQ33484065-4327C261-8134-4311-8323-C0D2882B9BDFQ33488700-BA6860CB-9FEF-4318-B4C6-AFE889BA5BF5Q33492805-7C0EC142-B7BF-41EC-B485-7AF3798DD6C2Q33554622-789C6160-9FE8-44EA-9875-C4CB8AADA392Q33557548-177C28BC-CCAB-4B31-BD94-17FFE5311D87Q33586122-A8DA3ACA-873A-473E-98F3-62F76646C09EQ33609458-6D20CE27-814E-4EE4-BEB6-626677DDC4E2Q33717891-CDA0AAAD-2413-4AA8-80B3-30175E3558E3Q33731220-B7E2B910-6E80-4E24-A7C1-AD3F87DED270Q33737498-13EB8BBC-1F40-44EB-97D8-402311394082Q33800747-603C0304-78A6-40F6-B9CA-A1E705C79040Q33835011-90569FFE-8DF4-4F3D-A398-4D1D7F8B7078Q33840997-2A7C6F86-F175-4C54-B35B-FD03AD663B04Q33876519-9717F226-DEE0-45CD-8538-232CB3573D8AQ33983425-2E43CE41-C966-42B9-8995-E72768781B0BQ34007430-DDE87652-FB10-47BE-960F-E2B869E46770Q34023444-E4564B24-9F8D-46B0-A907-897C5AAE6604Q34099620-EECA4A83-D57A-4D2C-AE4B-1D8901314D0F
P2860
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@en
type
label
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@en
prefLabel
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
@en
P2093
P356
P1476
Prognostic significance of autoimmunity during treatment of melanoma with interferon
@en
P2093
Alexandros Stratigos
Aristidis Polyzos
Catherine Stavropoulou-Giokas
Dimitrios Bafaloukos
Dimitrios Pectasides
Dimosthenis Tsoutsos
George Fountzilas
Helen Gogas
John Ioannovich
John M Kirkwood
P304
P356
10.1056/NEJMOA053007
P407
P577
2006-02-01T00:00:00Z